Journal
DIABETES OBESITY & METABOLISM
Volume 17, Issue 4, Pages 426-429Publisher
WILEY
DOI: 10.1111/dom.12439
Keywords
canagliflozin; diabetes complications; drug mechanism; SGLT2 inhibitor; type 2 diabetes
Categories
Funding
- Janssen Research AMP
- Development, LLC.
- Janssen Scientific Affairs, LLC.
Ask authors/readers for more resources
Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo-controlled phase III studies assessed the effect of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [ defined as baseline serum uric acid >= 475 mu mol/l (similar to 8mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a similar to 13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo-subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of < 360 mu mol/l (similar to 6mg/dl) with both canagliflozin 100mg (23.5%) and 300 mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with T2DM, including those with baseline hyperuricaemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available